Lyell Immunopharma, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Lyell Immunopharma, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, equals 85% of its market value (net cash). Higher than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-121.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 84% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / -64%In 3 years sales changed by -100% while total assets changed by -64%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-16.5×Operating cash was negative last year, while some debt falls due within a year.
Lower than 51% of Healthcare companies in United States.
Cash Cushion Ratio
+85%Cash, after subtracting all debt, equals 85% of its market value (net cash).
Higher than 86% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Lyell Immunopharma, Inc. made a loss over the last year. Lyell Immunopharma, Inc. owes $0.25 for every $1 it owns. Lyell Immunopharma, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossLyell Immunopharma, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.98The share price is 0.98 times Lyell Immunopharma, Inc.'s book value per share, lower than 79% of Healthcare companies in United States.
Market cap
$230 MThe total market value of all of Lyell Immunopharma, Inc.'s shares at today's price (share price × number of shares), smaller than 56% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$234 MWhat Lyell Immunopharma, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$9.54Net worth divided by the number of shares. The share price of $9.38 is 1.0 times this, which is the P/B above.
Return on equity (ROE)
-93.3%Lyell Immunopharma, Inc. lost 93.3% of its shareholders' money over the last year, lower than 69% of Healthcare companies in United States.
Owes vs Owns
0.25×Lyell Immunopharma, Inc. owes $0.25 for every $1 it owns (low), lower than 66% of Healthcare companies in United States.
Dividend yield
NoneLyell Immunopharma, Inc. does not currently pay a dividend.
Revenue growth
-41%Revenue fell 41% in the year to Dec 2025, and shrank 92% a year on average over 3 years.
Profit growth
LossLyell Immunopharma, Inc. made a loss in each of the last two years.
Profit margin
-762355.6%Lyell Immunopharma, Inc. lost $762356 for every $100 of revenue.
Cash vs debt
Net cashLyell Immunopharma, Inc. held $196 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Lyell Immunopharma, Inc.: $230 M ÷ $234 M (30 Jun 2026) = 1.0.
What is Lyell Immunopharma, Inc.'s return on equity?
Lyell Immunopharma, Inc. lost 93.3% of its shareholders' money over the last year, lower than 69% of Healthcare companies in United States.
How much does Lyell Immunopharma, Inc. owe compared with what it owns?
Lyell Immunopharma, Inc. owes $0.25 for every $1 it owns (low), lower than 66% of Healthcare companies in United States.
Does Lyell Immunopharma, Inc. pay a dividend?
No. Lyell Immunopharma, Inc. does not currently pay a dividend.
Is Lyell Immunopharma, Inc.'s revenue growing?
Revenue fell 41% in the year to Dec 2025, and shrank 92% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.